Skip to main content
Eledon Pharmaceuticals, Inc. logo

Eledon Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ELDN ISIN · US67011N2045 LEI · 549300S17CAM13O43606 US Professional, scientific and technical activities
Open in API
Filings indexed 585 across all filing types
Latest filing 2016-05-16 Regulatory Filings
Country US United States of America
Listing US ELDN

About Eledon Pharmaceuticals, Inc.

https://eledon.com/

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing immune-modulating therapies for organ transplantation and autoimmune diseases. The company's mission, "One Transplant for Life," focuses on improving transplant longevity and the quality of life for recipients. Its lead product candidate, tegoprubart, is an anti-CD40 Ligand (CD40L) antibody designed to regulate the immune system to prevent organ rejection. Eledon has completed a Phase 2 clinical trial evaluating tegoprubart in kidney transplant recipients and is advancing the compound into late-stage development. The company is also exploring tegoprubart's potential in other applications, including liver transplantation and xenotransplantation.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2016
Regulatory Filings
2016-05-16 English
10-Q
Interim / Quarterly Report Q1 2016
2016-05-10 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a definitive proxy statement and additional materials related to the company's annual meeting of shareholders. It includes information about the availability of proxy materials, voting instructions, and details about the annual meeting such as date, time, place, and director nominations. It does not contain the full annual report or financial statements but rather serves as proxy solicitation material. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length is about 5,079 characters, which is consistent with a proxy statement rather than a full annual report or other filings.
2016-04-29 English
DEF 14A
Proxy Solicitation & Information Statement
2016-04-29 English
PRIMARY DOCUMENT
Director's Dealing
2016-03-15 English
IRANNOTICE
Regulatory Filings Classification · 95% confidence The document is a notice referencing a disclosure filed in the Annual Report on Form 10-K for the fiscal year ended December 31, 2015. It states that the Annual Report was filed with the SEC on March 10, 2016. The document itself is a short letter providing notice of this filing, signed by the CFO. It does not contain the actual Annual Report or substantive financial data, but rather serves as a regulatory disclosure notice. Given the short length (953 characters) and the nature of the content, this fits the criteria for a Regulatory Filing (RNS) rather than the Annual Report (10-K) itself.
2016-03-10 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.